Solventum posts shareholder letter via SEC Reg FD report

Solventum Corporation furnished a letter to its shareholders under a Regulation FD disclosure.

Accepted by SEC EDGAR 12/16/2025 - 09:02 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Solventum Corporation furnished a letter to its shareholders under a Regulation FD disclosure.

On December 16, 2025, the company issued a shareholder letter and attached it as Exhibit 99.1 to a current report. The company states that this information is being furnished, not filed, so it is not subject to liability under Section 18 of the Exchange Act and will only be incorporated into other securities filings if specifically referenced. Solventum’s common stock, with a par value of $0.01 per share, trades on the New York Stock Exchange under the symbol SOLV.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Solventum Corporation (SOLV) disclose in this SEC filing?

Solventum Corporation disclosed that on December 16, 2025 it issued a letter to shareholders, which is furnished as Exhibit 99.1 under Item 7.01 Regulation FD Disclosure.

Where can investors find Solventum (SOLV)'s December 16, 2025 shareholder letter?

The shareholder letter is included in the filing as Exhibit 99.1, titled "Letter to Shareholders, December 16, 2025."

Is Solventum (SOLV)'s shareholder letter considered 'filed' with the SEC?

No. The company states that the information in Item 7.01 and Exhibit 99.1 is being furnished and shall not be deemed filed for purposes of Section 18 of the Exchange Act.

Will Solventum's shareholder letter be automatically incorporated into other SEC filings?

No. The company notes that the information and exhibit will not be incorporated by reference into other securities filings except if expressly set forth by specific reference in such a filing.

On which exchange does Solventum Corporation (SOLV) trade and under what ticker?

Solventum Corporation’s common stock trades on the New York Stock Exchange under the ticker symbol SOLV.

What exhibits are included in this Solventum (SOLV) current report?

The report lists Exhibit 99.1 (Letter to Shareholders, December 16, 2025) and Exhibit 104 (Cover Page Interactive Data File with inline XBRL tags).

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

FALSE000196473800019647382025-12-162025-12-16

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): December 16, 2025

SOLVENTUM CORPORATION

(Exact Name of Registrant as Specified in Its Charter)

Delaware

File No. 001-41968

92-2008841

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

3M Center, Building 275-6W 2510 Conway Avenue East, Maplewood, Minnesota

55144

(Address of Principal Executive Offices)

(Zip Code)

(Registrant’s Telephone Number, Including Area Code) (651) 733-1110

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, Par Value $.01 Per Share

SOLV

New York Stock Exchange

Securities registered pursuant to section 12(g) of the Act: None

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company     ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the exchange Act.     ☐

Item 7.01. Regulation FD Disclosure

On December 16, 2025, Solventum Corporation issued a letter to its shareholders. A copy of the shareholder letter is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

In accordance with General Instruction B.2 of Form 8-K, the information contained in Item 7.01 and attached as Exhibit 99.1 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information and exhibit be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

Exhibit Number						Description
99.1						Letter to Shareholders, December 16, 2025
104						Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			SOLVENTUM CORPORATION
			By:			/s/ Wayde McMillan
						Wayde McMillan
						Executive Vice President and Chief Financial Officer

Dated: December 16, 2025